A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors
CB307 was well tolerated as a monotherapy and in combination with pembrolizumab, and tumor responses were observed in patients with metastatic castration-resistant prostate cancer. See related commentary by Nguyen and Luke, p. 3356.
Authors
- Phillip D. Bartlett (ORCID: https://orcid.org/0000-0002-2016-944X)
- Alejandro Falcón (ORCID: https://orcid.org/0000-0003-4531-5877)
- Minjung Song (ORCID: https://orcid.org/0009-0001-6046-2392)
- Anuradha Jayaram (ORCID: https://orcid.org/0000-0002-5255-8909)
- Jessica E. Hawley (ORCID: https://orcid.org/0000-0003-1720-5654)
- Julia Martínez‐Pérez (ORCID: https://orcid.org/0000-0003-0634-4974)
- Valentina Boni (ORCID: https://orcid.org/0000-0002-8675-0018)
- Philip Bland‐Ward (ORCID: https://orcid.org/0009-0005-7126-0699)
- Òscar Reig (ORCID: https://orcid.org/0000-0003-1166-6943)
- Daniel Castellano (ORCID: https://orcid.org/0000-0002-9106-0687)
- Maja J.A. de Jonge (ORCID: https://orcid.org/0000-0002-1938-226X)
- Ignacio Melero (ORCID: https://orcid.org/0000-0002-1360-348X)
- Bernard Doger de Spéville (ORCID: https://orcid.org/0009-0004-3264-5433)
- José Luis Perez‐Gracia (ORCID: https://orcid.org/0000-0003-4941-9075)
- Elisabeth G.E. de Vries (ORCID: https://orcid.org/0000-0002-8949-7425)
- Anja Williams (ORCID: https://orcid.org/0000-0002-4944-1558)
- Andrew J. Leishman (ORCID: https://orcid.org/0000-0003-4273-8188)
- Irene Moreno (ORCID: https://orcid.org/0000-0001-5027-6388)
- Johann Sebastian De Bono (ORCID: https://orcid.org/0000-0002-2034-595X)
- Kenji Hashimoto (ORCID: https://orcid.org/0000-0001-8826-2037)
- Derk Jan de Groot (ORCID: https://orcid.org/0000-0002-8306-6835)
- Eelke Gort (ORCID: https://orcid.org/0000-0001-7390-0761)
- Geòrgia Anguera (ORCID: https://orcid.org/0000-0002-6060-1110)
- Andrew J. Pierce (ORCID: https://orcid.org/0000-0001-9062-0307)
- Daan G. Knapen (ORCID: https://orcid.org/0000-0002-2523-137X)
- José Luis Alonso-Romero (ORCID: https://orcid.org/0000-0001-8746-2096)
- Peter Lloyd (ORCID: https://orcid.org/0009-0007-2337-7459)
- Kevin Duffy
- Albert Chau (ORCID: https://orcid.org/0000-0002-5141-1710)
Institutions
- Royal Marsden NHS Foundation Trust (GB)
- University Medical Center Groningen (NL)
- Institute of Cancer Research (GB)
- Sarah Cannon Research Institute (GB)
- University of Washington (US)
- Quorn (United Kingdom) (GB)
- Hospital de Sant Pau (ES)
- University Medical Center Utrecht (NL)
- Research Institute Hospital 12 de Octubre (ES)
- London Cancer (GB)
- Hospital Universitario Dexeus (ES)
- Hospital Universitario 12 De Octubre (ES)
- Hospital Universitario Quirónsalud Madrid (ES)
- Hospital Clínic de Barcelona (ES)
- Cancer Genomics Centre (NL)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Clinica Universidad de Navarra (ES)
- Hospital Universitario HM Sanchinarro (ES)
- Erasmus MC Cancer Institute (NL)
- Hospital Universitario Virgen de la Arrixaca (ES)
- Hospital Universitario Virgen del Rocío (ES)
- Fundació Clínic per a la Recerca Biomèdica (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- US Biologic (United States) (US)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- University College London (GB)
- Universitat de Barcelona (ES)
- Universidad de Navarra (ES)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3581
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09